| Interrupting subcutaneous immunotherapy is advised. |
|---|
| Interrupting sublingual immunotherapy is advised. |
| Both subcutaneous and sublingual immunotherapy should be discontinued in symptomatic patients with exposure or contact SARS‐CoV‐2‐positive individuals, or patients with positive test results (RT‐PCR). |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.